Theriva Biologics To Discuss The Trial Design For VIRAGE - A Phase 2b Clinical Study Of Systemically Administered VCN-01 In Combination With Chemotherapy In Pancreatic Ductal Adenocarcinoma At The 2024 ASCO Annual Meeting

Theriva Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on th

BenzingaApr 25 08:34 ET

Express News | Theriva Biologics Disclosed Positive Topline Data From Investigator Sponsored Phase 1 Trial Of Intravitreal VCN-01 In Pediatric Patients With Refractory Retinoblastoma

Moomoo 24/7Apr 23 08:40 ET

Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

Shares of Hibbett, Inc. (NASDAQ:HIBB) rose sharply in today's pre-market trading after the company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash, in a $1.1 billion transactio

BenzingaApr 23 08:00 ET

Theriva Biologics' VCN-01 Shows Promise in Pediatric Cancer Trial

TipRanksApr 23 07:12 ET

Express News | Theriva Biologics Inc - Intravitreal Vcn-01 Demonstrated Promising Antitumor Activity and Did Not Appear to Change Retinal Function

Moomoo 24/7Apr 23 07:01 ET

Express News | Theriva Biologics Inc - Vcn-01 Was Well Tolerated After Intravitreal Administration at 2 Doses

Moomoo 24/7Apr 23 07:01 ET